Garcia José Mauricio, Mendonça Luisa, Brant Rodrigo, Abud Murilo, Regatieri Caio, Diniz Bruno
José Mauricio Garcia, Luisa Mendonça, Murilo Abud, Bruno Diniz, Department of Ophthalmology, Universidade Federal de Goiás, Goiânia 74001-970, Brazil.
World J Stem Cells. 2015 Jan 26;7(1):160-4. doi: 10.4252/wjsc.v7.i1.160.
In this review, we discuss about current knowledge about stem cell (SC) therapy in the treatment of retinal degeneration. Both human embryonic stem cell and induced pluripotent stem cell has been growth in culture for a long time, and started to be explored in the treatment of blinding conditions. The Food and Drug Administration, recently, has granted clinical trials using SC retinal therapy to treat complex disorders, as Stargardt's dystrophy, and patients with geographic atrophy, providing good outcomes. This study's intent is to overview the critical regeneration of the subretinal anatomy through retinal pigment epithelium transplantation, with the goal of reestablish important pathways from the retina to the occipital cortex of the brain, as well as the differentiation from pluripotent quiescent SC to adult retina, and its relationship with a primary retinal injury, different techniques of transplantation, management of immune rejection and tumorigenicity, its potential application in improving patients' vision, and, finally, approaching future directions and challenges for the treatment of several conditions.
在本综述中,我们讨论了关于干细胞(SC)疗法治疗视网膜变性的当前知识。人类胚胎干细胞和诱导多能干细胞都已在培养中生长了很长时间,并开始在治疗致盲疾病方面进行探索。美国食品药品监督管理局最近批准了使用SC视网膜疗法治疗复杂疾病的临床试验,如斯塔加特氏营养不良症和地图样萎缩患者,并取得了良好效果。本研究的目的是概述通过视网膜色素上皮移植实现视网膜下解剖结构的关键再生,目标是重建从视网膜到大脑枕叶皮质的重要通路,以及多能静止SC向成人视网膜的分化,及其与原发性视网膜损伤、不同移植技术、免疫排斥和致瘤性管理的关系,其在改善患者视力方面的潜在应用,最后探讨治疗多种疾病的未来方向和挑战。